Manipulating selectivity through gatekeeper interactions: Inhibition of EGFR and its T790M mutant

被引：0

作者：

Hanan, Emily ^{[1
]}

Bryan, Marian ^{[1
]}

Burdick, Daniel ^{[1
]}

Chan, Bryan ^{[1
]}

Chen, Yuan ^{[1
]}

Eigenbrot, Charles ^{[1
]}

Heald, Robert ^{[2
]}

Heffron, Timothy ^{[1
]}

La, Hank ^{[1
]}

Purkey, Hans ^{[1
]}

Schaefer, Gabriele ^{[1
]}

Schmidt, Stephen ^{[1
]}

Seward, Eileen ^{[2
]}

Sideris, Steve ^{[1
]}

Wang, Shumei ^{[1
]}

Yu, Christine ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

[2] Discovery Charles River, Harlow, Essex, England

来源：

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2016年 / 252卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

620

引用

页数：1

共 50 条

[41] EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Yamada, Teppei
Azuma, Koichi
Muta, Emi
Kim, Jintaek
Sugawara, Shunichi
Zhang, Guang Lan
Matsueda, Satoko
Kasama-Kawaguchi, Yuri
Yamashita, Yuichi
Yamashita, Takuto
Nishio, Kazuto
Itoh, Kyogo
Hoshino, Tomoaki
Sasada, Tetsuro
PLOS ONE, 2013, 8 (11):
[42] Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M
Zhao, Sha
Li, Xuefei
Zhao, Chao
Jiang, Tao
Jia, Yijun
Shi, Jinpeng
He, Yayi
Li, Jiayu
Zhou, Fei
Gao, Guanghui
Li, Wei
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
LUNG CANCER, 2019, 128 : 33 - 39
[43] A novel multi-target inhibitor harboring selectivity of inhibiting EGFR T790M sparing wild-type EGFR
Song, Xiaoping
Qi, Xin
Wang, Qiang
Zhu, Weiming
Li, Jing
AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1884 - 1898
[44] TAS-2913 is a Mutant Selective EGFR Inhibitor for NSCLC: Characterization Against EGFR T790M in Cell and Xenograft Models
Miyadera, K.
Kato, M.
Takahashi, I.
Ito, K.
Aoyagi, Y.
Fukasawa, K.
Sagara, T.
Yonekura, K.
Iwasawa, Y.
Utsugi, T.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 44 - 44
[45] Tracking spatiotemporal T790M heterogeneity in patients with EGFR-mutant advanced NSCLC after acquired resistance to EGFR TKIs
Zhang, Y-C.
Pi, C.
Ke, E-E.
Chen, Z-H.
Su, J.
Dong, Z-Y.
Xu, C-R.
Yan, H-H.
Tu, H-Y.
Zhong, W-Z.
Zhang, X-C.
Yang, J-J.
Yang, X-N.
Zhou, Q.
Wu, Y-L.
ANNALS OF ONCOLOGY, 2016, 27
[46] Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs
Zhang, Yi-Chen
Pi, Can
Ke, E-E
Chen, Zhi-Hong
Su, Jian
Dong, Zhong-Yi
Xu, Chong-Rui
Tu, Hai-Yan
Yan, Hong-Hong
Zhong, Wen-Zhao
Yang, Jin-Ji
Zhang, Xu-Chao
Wu, Yi Long
Zhou, Qing
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1249 - S1249
[47] Reduced sensitivity for EGFR T790M mutations using the Idylla EGFR Mutation Test
Lee, Eric
Jones, Victoria
Topkas, Eleni
Harraway, James
JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (01) : 43 - 47
[48] ASTRIS real world study of osimertinib in patients (pts) with EGFR T790M NSCLC: Efficacy analysis by tissue or plasma T790M test
Freitas, H. C.
Park, K.
Kim, D-W.
Tiseo, M.
Hochmair, M. J.
Chang, G-C.
Shi, Y-K.
Moran, T.
Chen, Y.
Laskin, J.
Solomon, B.
Miranda, M.
Rigas, J.
Cheema, P. K.
Kim, S-W.
ANNALS OF ONCOLOGY, 2018, 29 : 149 - 149
[49] Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naive EGFR-Mutant Lung Adenocarcinomas
Cabanero, M.
Kuo, J.
Liu, N.
Tsao, M.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S443 - S443
[50] Plasma T790M Result Alters Treatment Options in a Previously T790 Wild-Type EGFR-Mutant Lung Cancer
Piotrowska, Zofia
Drapkin, Benjamin
Engelman, Jeffrey A.
Nagy, Rebecca J.
Lanman, Richard B.
Sequist, Lecia V.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : E95 - E97

← 1 2 3 4 5 →